Convened under the auspicious of esteemed endorsers - ISTA

James Mason - School Of Health, Durham University - Stockton on Tees, United KingdomIntroduction*Email: msukeik@hotmail.comTotal hip replacements (THR) are associated with significant blood loss that requires thetransfusion of allogeneic blood. Although safer than ever, allogeneic blood transfusion is stillassociated with risks to the recipients.Tranexamic acid (TXA) is a fibrinolytic inhibitor which has been used to reduce blood loss andtransfusion in hip and knee arthroplasties, with variable results.This meta-analysis aims to investigate the efficacy of TXA in reducing blood loss andallogeneic blood transfusion after THR and to assess whether it’s use is associated with a higherrisk of developing complications such as deep venous thrombosis (DVT), pulmonary embolism(PE), infection, ischaemic heart diseases and mortality.MethodsA systematic review and meta-analysis of published randomised controlled trials (RCTs) whichused TXA to reduce blood loss and transfusion in hip arthroplasty were conducted. The datawas evaluated using the generic evaluation tool designed by the Cochrane Bone, Joint andMuscle Trauma Group.ResultsWe identified 11 clinical trials which were considered suitable for detailed data extraction.There were no trials which utilised TXA in revision THR.Blood loss: Seven studies (350 patients) were eligible. Using TXA reduced intraoperative bloodloss by an average of 104 ml (95% Confidence Interval (CI) -164 to -44, P-value 0.0006,Heterogeneity I 2 0%), postoperative blood loss by an average of 172 ml (95%CI -263 to -81, P-value 0.0002, Heterogeneity I 2 63%) and total blood loss by an average of 289 ml (95%CI -440to -138, P-value